Skip to main content
SpringerLink
Log in

Pharmacological Agents as Tools in Psychiatric Research

  • Chapter
The Impact of Biology on Modern Psychiatry

  • 39 Accesses

Abstract

We thought we might approach this problem by exploring the effects of pharmacologically active agents as tools in modifying behavior in the different disease states, in the hope that this might resolve questions of psychoses as either a continuum or as separate and distinct disorders. Secondly - examine these findings in regard to current theories of psychoses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anden, N.D., Corrodi, H., Fuxe, K.: Turnover studies using synthesis inhibition. In: Metabolism of amines in the brain, G. Hopper, ed. Macmillan, New York, pp. 38–47, 1969.

    Google Scholar 

  2. Angrist, B.M., Gershon, S.: The phenomenology of experimentally-induced amphetamine psychosis: Preliminary Observations. Biol. Psychiat. 2. pp. 95–107, 1970.

    PubMed  CAS  Google Scholar 

  3. Angrist, B., Sathananthan, G., and Gershon, S.: Behavioral effects of 1-DOPA in schizophrenic patients. Psycho-pharmacologia 31: 1–2, 1973.

    Article  CAS  Google Scholar 

  4. Angrist, B.M., Sathananthan, G., Wilk, S., and Gershon, S.: Behavioral and biochemical effects of 1-DOPA in psychiatric patients. In: Frontiers in Catecholamine Research ed. by E. Usdin and S. Snyder, Pergamon, Oxford, PP.991–994.,1973.

    Google Scholar 

  5. Angrist, B.M., and Gershon, S.: The phenomenology of experimentally-induced amphetamine psychosis. Preliminary Observations. Biol. Psychiat. 2: 95–107, 1970.

    PubMed  CAS  Google Scholar 

  6. Angrist, B., Gershon, S.: Dopamine and psychotic states: Preliminary remarks, In: Advances in Biochemical Psychopharmacology, Vol. 12, edited by E. Usdin, Raven Press, New York. pp. 211–219, 1974.

    Google Scholar 

  7. Angrist, B.M., Shopsin, B., and Gershon, S.: The comparative psychotomimetic effects of stereoisomers of amphetamine. Nature, 234: 152–153, 1971.

    Article  PubMed  CAS  Google Scholar 

  8. Angrist, B.M., Thompson, H., Shopsin, B., and Gershon, S.: Clinical studies with dopamine receptor stimulants. Psychopharmacologia (Berl.) 44: 273–280, 1975.

    Article  CAS  Google Scholar 

  9. Araki, I., Ito, M., Kostyuk, P., Oscarsson, O., and Oshima, I.: The effects of alkaline cations on the responses of cat spinal neurons and their removal from the cell. Proc. R. Soc. Lond. (Biol.), 162: 319, 1965.

    Article  CAS  Google Scholar 

  10. Aronoff, M.S., and Epstein, R.S.: Lithium failure in mania: A clinical study. Annual Mtg. of American Psychiatric Association, Bal Harbor, Florida. 1969.

    Google Scholar 

  11. Baldessarini, R.J., and Stephens, J.H.: Lithium carbonate for affective disorders. Arch. Gen. Psychiatry, 22: 72, 1970.

    Article  PubMed  CAS  Google Scholar 

  12. Berlet, H.H., Matsumoto, K., Pscheidt, G.R., Spaide, J., Bull, C, and Himwich, H.E.: Biochemical correlates of behavior in schizophrenic patients. Arch. Gen. Psychiatry, 13: 521–531, 1970.

    Article  Google Scholar 

  13. Brogden, R.N., Spieght, T.M., and Avery, G.S.: Levodopa: A review of pharmacological properties and therapeutic uses with particular reference to Parkinson’s disease. Drugs. 2: 257–408, 1971.

    Article  Google Scholar 

  14. Brune, G.G., Pscheidt, G.R., and Himwich, H.E.: Different responses of urinary tryptamine and of total catecholamines during treatment with reserpine and iscarboxazid in schizophrenic patients. Int. J. Neuropharmacol. 2: 17–23, 1963.

    Article  CAS  Google Scholar 

  15. Buchsbaum, M., Goodwin, F., Murphy, D.L., and Borge, G.: Average evoked response in affective disorders. Am. J. Psychiatr., 128 (1): 19–25, 1971.

    PubMed  CAS  Google Scholar 

  16. Bunney, W.E., Jr., Murphy, D.L., Goodwin, F.K. and Borge, G.: The switch process from depression to mania: Relationship to drugs which alter “brain amines. Lancet, 1: 1022–1027, 1970.

    Article  PubMed  Google Scholar 

  17. Chase, T.N.: Clinical studies of dopaminergic mechanisms. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin, ed. Raven Press, New York, pp. 427–434. 1974.

    Google Scholar 

  18. Chase, T.N., Shoulson, I.: Dopaminergic mechanisms in patients with extrapyramidal disease. In: Advances in neurology, Vol. 9, D.B. Calne, T.N. Chase and A. Barbeau, eds. Raven Press, New York, pp. 359–366. 1975.

    Google Scholar 

  19. Connell, P.H.: Amphetamine Psychosis. Maudsley Monographs No.5 Oxford Univ. Press, London. 1958.

    Google Scholar 

  20. Cooper, J.E., Kendall, R.E., Gurland, B.J., Sartorius, N., and Parkas, T.: Cross national study of diagnoses of mental disorders. Am. J. Psychiatry, 125: 21–29,1969.

    Google Scholar 

  21. Corrodi, H., Fuxe, K., Ungerstedt, U.: Evidence for a new type of dopamine receptor stimulating agent. J. Pharm. Pharmacol. 23: 989–991, 1971.

    Article  PubMed  CAS  Google Scholar 

  22. Costall, B., Naylor, R.J.: On the mode of action of apomorphine, Europ. J.,Pharmacol. 21: 350–361, 1973b.

    CAS  Google Scholar 

  23. Costall, B., Naylor, R.J.: Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical effect? Psychopharmacologia (Berl.) 32: 161–170. 1973a.

    Article  CAS  Google Scholar 

  24. Cotzias, G.C.: Levodopa, manganese and degenerations of the brain, harvey society lectures. Delivered 1972 under the auspices of the Harvey Society Series 68, pp. 115–147, New York, Academic Press. 1974.

    CAS  Google Scholar 

  25. Creese, I.: Behavioral evidence of dopamine receptor stimulation “by piribedil (ET-495) and its metabolite S 584. Europ. J. Pharmacol. 28: 55–58, 1974.

    Article  CAS  Google Scholar 

  26. Davis, J.M. and Janowsky, D. S.: Amphetamine and methylphenidate psychosis. In: Frontiers in Catecholamine Research Pergamon, Oxford, pp. 977–981, 1973.

    Google Scholar 

  27. Duby, S.E., Cotzias, G.C., Papayasiliou, P.S., Lawrence, W.H.: Injected apomorphine and orally administered levodopa in Parkinsonism. Arch. Neurol. (Chic). 27: 474–480. 1972.

    Article  CAS  Google Scholar 

  28. Dunkley, B., Sanghvi. I., Friedman, E., Gershon, S.: Comparison of behavioral and cardiovascular effects of 1-DOPA and 5-HTP in conscious dogs. Psychopharmacologia (Berl.) 26: 161–172, 1972.

    Article  CAS  Google Scholar 

  29. Ellinwood, E.H., Jr., Sudilowsky, A., Nelson, L.: Behavioral analysis of chronic amphetamine intoxication. Biol. Psychiat. 4: 215–230, 1972.

    PubMed  Google Scholar 

  30. Ernst, A.M.: Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia (Berl.) 10: 316–323, 1967.

    Article  CAS  Google Scholar 

  31. Everett, G.M., Borcherding, J.W.: 1-DOPA: Effect on concentration of dopamine, norepinephrine, and serotonin in brains of mice. Science, 168: 849–850, 1970.

    Article  PubMed  CAS  Google Scholar 

  32. Feldman, P.E.: The treatment of anergic schizophrenia with imipramine. J. Clin., Exp. Psychopath., 20: 235, 1959

    CAS  Google Scholar 

  33. Fram, D.H., Murphy, D.L., Goodwin, F.K., Keith, H., Brodie, H., Bunney, W.E., Jr. and Snyder, F.: 1-DOPA and sleep in depressed patients. Psychophysiology 7: 316–317, 1970.

    Google Scholar 

  34. Friedman, E., Gershon, S.: 1-DOPA: Centrally mediated emission of seminal fluid in male rats. Life Sci., 11: 435–440, 1972.

    Article  CAS  Google Scholar 

  35. Fries, H.: Experience with lithium carbonate treatment at a psychiatric department in the period 1964-1967. Acta Psychiatr. Scand. (Suppl), 207: 41, 1969.

    Article  Google Scholar 

  36. Fuxe, K., Agnate, L.F., Corrodi, H., Everitt, B.J., Hokfelt, T. Lofstrom, J., Ungerstedt, U.: Action of dopamine receptor agonists in forebrain and hypothalamus: Rotational behavior, ovulation and dopamine turnover. In: Advances in neurology, Vol. 9, D.B. Calne, T.N. Chase, and A. Barbeau, eds.. Raven Press, New York, pp. 223–242, 1975.

    Google Scholar 

  37. Garratini, S., Barreggi, S., Marc, Y., Calderini, G., Marsella, P.L.: Effects of pirobedil on noradrenaline and MOPEGSO4 levels in the rat brain. Europ. J. Pharmacol. 28: 214–2l6

    Google Scholar 

  38. Gershon, S., Holmberg, G., Mattson, E., and Mattson, N.: Imipramine hydrochloride. Arch. Gen. Psychiatry. 6: 96–101. 1962.

    Article  PubMed  CAS  Google Scholar 

  39. Gershon, S., and Shaw, F.H.: Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet, 1: 1371–1374, 1961.

    Article  PubMed  CAS  Google Scholar 

  40. Glessinger, B.: Evaluation of lithium in treatment of psychotic excitement. Med. J. Aust. 41: 277, 1954.

    Google Scholar 

  41. Goldberg, L.I.: Comparison of putative dopamine receptors in blood vessels and the central nervous system. In: Advances in neurology, Vol. 9, D.B. Calne, T.N. Chase, and A. Barbeau, Eds. Raven Press, New York, pp. 53–56 1975.

    Google Scholar 

  42. Goldstein, M., Battista, A.F., Ohmoto, T., Anagnoste, B., Fuxe, K.: Tremor and involuntary movements in monkeys: Effects of 1-DOPA and of a dopamine receptor stimulating agent. Science, 179: 816–817, 1973.

    Article  PubMed  CAS  Google Scholar 

  43. Goldner, R.D.: Control of minor sexual compulsions with Imipramine and amine oxidase regulators. Third World Congr. Psychiatry, 2: 1155, 196l.

    Google Scholar 

  44. Goodwin, F.K.: Behavioral effects of 1-DOPA in man. In: Psychiatric Complications of Medical Drugs, Ed. by R.I. Shader, Raven Press, New York, pp. 149–174, 1972.

    Google Scholar 

  45. Goodwin, F.K., Murphy, D.L., Brodie, H.K.H. and Bunney, W.E., Jr.: 1-Dopa, catecholamines and behavior: A clinical and biochemical study in depressed patients. Biol. Psychiatry, 2: 341–366, 1970.

    PubMed  CAS  Google Scholar 

  46. Greenblatt, M., Grosser, G.H., and Wechsler, H.: A comparative study of selected antidepressant medications and EST. Am. J. Psychiatry, 119: 144–153, 1962.

    PubMed  CAS  Google Scholar 

  47. Greenfield, I., Zuger, M., Bleak, R.M., and Bakal, S.F.: Lithium chloride intoxication. New York State J. Med. 50: 549, 1950.

    Google Scholar 

  48. Griffith, J.J., Cavanaugh, J.H., and Oates, J.A.: Psychosis induced by the administration of d-amphetamine to human volunteers. In: Psychotomimetic Drugs, edited by D.H. Efron, Raven Press, New York, p. 28, 1970.

    Google Scholar 

  49. Grob, D., Harvey, A.M., Langworthy, O.R., and Lilienthal, J.R., Jr.: The administration of di-isopropyl fluorophosphate (DFP) to man. III. Effect on the central nervous system with special reference to the electrical activity of the “brain. Johns Hopkins Med. J., 81: 217, 1947.

    Google Scholar 

  50. Hartigan, G.P.: The use of lithium salts in affective disorders. Br. J. Psychiatry, 109: 810, 1963.

    Article  PubMed  CAS  Google Scholar 

  51. Janowsky, D.S., Davis, J.M.: Dopamine, psychomotor stimulants and schizophrenia: Effects of methylphenidate and the stereoisomers of amphetamine in schizophrenics. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin, ed.Raven Press, New York, pp. 317–323, 1974.

    Google Scholar 

  52. Johnson, G., Gershon, S., and Hekimian, L.J.: Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: An interim report. Compr. Psychiatry, 9: 563, 1968.

    Article  PubMed  CAS  Google Scholar 

  53. Johnson, G., Hekimian, L., and Gershon, S.: Differential drug responsiveness in psychiatric subjects. 8th Annual ACNP Mtg., San Diego, California. 1970.

    Google Scholar 

  54. Karobath, M., Diaz, J.L., Huttunen, M.O.: The effect of 1-DOPA on the concentrations of tryptophan, tyrosine, and serotonin in rat brain. Europ. J. Pharmacol. 4: 393–396. 1971.

    Article  Google Scholar 

  55. Klein, D.F.: Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia, 5: 397, 1964.

    Article  PubMed  CAS  Google Scholar 

  56. Kuhn, R.: Uber die Behandlung depressiver Zustande mit einem Iminobenzyldervat. Schweiz. Med. Wochenschr. 87: 1135, 1957.

    PubMed  CAS  Google Scholar 

  57. Kuhn, R.: The treatment of depressive states with G-22355. Am. J. Psychiatry, 115–459, 1958.

    Google Scholar 

  58. Lehmann, H.E., and Ban, T.A.: Clinical use of other antipsychotic agents. In: Principles of Psychopharmacology, edited by W.G. Clark and J. del Giudice, Academic Press, New York, p. 621. 1970.

    Google Scholar 

  59. Leiberman, A., LE Brun, Y., Dinkar, B., Zolfaghari, M.: The use of dopaminergic receptor stimulating agent (Piribedil, ET-495) in Parkinson’s disease. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin ed.Raven Press, New York, pp. 415–425

    Google Scholar 

  60. Leyberg, J.T., and Denmark, J.C.: The treatment of depressive states with Imipramine hydrochloride. Br. J. Psychiat. 105: 1123, 1959.

    Article  CAS  Google Scholar 

  61. Lewander, T: Effect of chronic-treatment with central stimu-lants on brain monoamines and some behavioral and physiological functions in rats, guinea pigs and rabbits. In: Advances in Biochemical Psychopharmacology Vol. 12 edited by E. Usdin,Raven Press, New York, pp. 221–239, 1974.

    Google Scholar 

  62. Lewander, T.: Effect of chronic-treatment with central stimulants on brain monoamines and some behavioral and physiological functions in rats, guinea pigs and rabbits. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin, ed.,Raven Press, New York, pp. 221–239, 1974.

    Google Scholar 

  63. Maj J., Pawlowski, L: The hypothermic effect of 1-DOPA in the rat. Life Sci. 13: 141–149, 1973.

    Article  PubMed  CAS  Google Scholar 

  64. Mayfield, D., and Brown, R.G.: The clinical laboratory and electroencephalographic effects of lithium. J. Psychiat. Res. 4: 207, 1966.

    Article  PubMed  CAS  Google Scholar 

  65. Moracci, E.: AZ ione di alcuni sali applicati direttamente sui centri corticali sensitivo-Motori del cane. Arch. Fisiol., 29: 487, 1931.

    Google Scholar 

  66. Murphy, D.L., Brodie, H.K.H., Goodwin, F.K., and Bunney, W.E. Jr.: 1-DOPA: Regular induction of hypomania in bipolar manic-depressive patients. Nature. 229: 135–136, 1971.

    Article  PubMed  CAS  Google Scholar 

  67. Nymark, M.: Apomorphine provoked stereotypy in the dog. Psychopharmacologia (Berl.) 26: 361–368, 1972.

    Article  PubMed  CAS  Google Scholar 

  68. Paul, M.I., Cramer, H., and Bunney, W.E. Jr.: Urinary cyclic AMP in the switch process from depression to mania. Science, 171: 300–313., 1971.

    CAS  Google Scholar 

  69. Pfeiffer, C.Z., Singh, M., and Goldstein, L.: Single dose-effect relationship of lithium on the electrical activity of cerebral cortex and of the heart. J. Clin. Pharmacol., 9: 298, 1969.

    CAS  Google Scholar 

  70. Pilkington, T.L.: A report on “Tofranil” in mental deficiency. Am. J. Ment. Defic., 66: 729, 1962.

    PubMed  CAS  Google Scholar 

  71. Pollack, B.: Clinical findings in the use of Tofranil in depressive and other psychiatric states. Am. J. Psychiatry, 116: 312, 1959.

    PubMed  CAS  Google Scholar 

  72. Pollin, W., Cordon, P.V. and Kety, S.S.: Effects of amino acid feedings in schizophrenic patients treated with ipro-niazid. Science, 133: 104–105, 1961.

    Article  PubMed  CAS  Google Scholar 

  73. Randrup. A., Munkvad, I.: Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia (Berl.) 11, 300–310, 1967.

    Article  CAS  Google Scholar 

  74. Rees, L., and Benaim, S.: An evaluation of iproniazid in the treatment of depression. Br. J. Psychiatry, 106: 193–202, 1960.

    Article  CAS  Google Scholar 

  75. Rochford, J.M., Detre, T., Tucker, G.J., Harrow, M.: Neuropsychological impairments in functional psychiatric disease. Arch. Gen. Psychiatry, 22: 114, 1970.

    Article  PubMed  CAS  Google Scholar 

  76. Rotrosen, J., Wallach, M.B., Angrist, B., Gershon, S.: Antagonism of apomorphine induced stereotypy and emesis in dogs by thioridazine, haloperidol, and pimozide. Psychopharmacologia (Berl.) 26: 185–194, 1972.

    Article  CAS  Google Scholar 

  77. Rountree, D.W., Nevin, S., and Wilson, A.: The effects of diisoprophylfluorophosphonate in schizophrenia and manic depressive psychosis. J. Neurol. Neurosurg. Psychiatry. 13: 47–62, 1950.

    Article  Google Scholar 

  78. Sathananthan, G., Angrist, B.M., and Gershon, S.: Response threshold to 1-DOPA in psychiatric patients. Biol. Psychiatry, 7: 139–149, 1973.

    PubMed  CAS  Google Scholar 

  79. Schou, M.: Lithium in psychiatric therapy. Psychopharmacologia, 1: 65, 1959.

    Article  PubMed  CAS  Google Scholar 

  80. Schou, M., Juel-Nielson, N., Stromgren, E., and Boldby, H.: The treatment of manic psychoses by the administration of lithium salts. J. Neurol. Neurosurg, Psychiatry. 17: 250, 1954.

    Article  CAS  Google Scholar 

  81. Schwab, R.S., Amador, L.V., Lettvin, J.Y.: Apomorphine in Parkinson’s disease. Trans. Amer. Neurol. Ass. 76: 251–263, 1951.

    Google Scholar 

  82. Shopsin, B., Kim, S.S. and Gershon, S.: A controlled study of lithium vs. chlorpromazine in acute schizophrenics. Brit. J. Psychiatry, 119: 435–440, 1971.

    CAS  Google Scholar 

  83. Shopsin, B., Johnson, G., and Gershon, S.: Neurotoxicity with lithium: differential drug responsiveness. Int. Pharmacopsychiatry. 1970.

    Google Scholar 

  84. Sivadon, P., and Chanoit, P: Clinical experience with lithium treatment of psychomotor excitation. Ann. Medicopsychol. 113: 790, 1955.

    PubMed  Google Scholar 

  85. Snyder, S.H.: Amphetamine psychosis: a “model” schizophrenia mediated by catecholamines. Am. J. Psychiatry, 130: 61–67, 1973.

    PubMed  CAS  Google Scholar 

  86. Spensley, J. and Rockwell, D.A.: Psychosis during methylpheni-date abuse. New Engl. J. Med. 286: 880–881, 1972.

    Article  PubMed  CAS  Google Scholar 

  87. Spring, G.K., Schweid, D., Gray, C, Steinberg, J. and Harwitz, M.: A double blind comparison of lithium and chlorpromazine in the treatment of manic states. Am. J. Psychiatry, 126: 1306, 1970.

    PubMed  CAS  Google Scholar 

  88. Strian, F., Michler, E., Benkert, P.: Tremor inhibition in Parkinson syndrome after apomorphine administration under 1-DOPA and decarboxylase inhibitor basic therapy. Pharmakopsychiat.5: 198–205, 1972.

    Article  Google Scholar 

  89. Turner, W. and Merlis, S.:A clinical trial of pargyline and and 1-DOPA in psychotic subjects. Dis. Nerv. Syst. 24: 538–541, 1964.

    Google Scholar 

  90. Ungerstedt, U.: Postsynaptic supersensitivity after 6-hydroxy-dopamine-induced degeneration of the nigrotriatal dopamine system. Acta. Physiol. Scand., Suppl. 367: 69–93, 1971.

    CAS  Google Scholar 

  91. VAN Beek, M.C., Timmerman, H.: Some benzhydryl derivatives as central dopamine receptor stimulating agents. J. Pharm. Pharmacol. 26: 57–58, 1974.

    Article  PubMed  Google Scholar 

  92. Wallach, M.B.: Drug-induced stereotyped behaviour: similarities and differences. In: Advances in Biochemical Psycho-pharmacology, Vol. 12, edited by E. Usdin,Raven Press, New York, pp. 241–260, 1974.

    Google Scholar 

  93. Walters, J., Bunney, B.S., Roth, R.H.: Piribedil and apomor-phine: Pre-and postsynaptic effects on dopamine synthesis and neuronal activity. In: Advances in neurology, Vol. 9, D.B. Calne, T.N. Chase and A. Barbeau eds.,Raven Press, New York, pp. 273–284, 1975.

    Google Scholar 

  94. Willner, J.H., Samach, M., Angrist, B.M., Wallach, M.B., Gershon, S.: Drug-induced stereotyped behavior and its antagonism in dogs. Commun. Behav. Biol. 5: 135–141. 1970.

    Google Scholar 

  95. Wyatt, R.J., Chase, T.N. and Englemen, K.: Effect of 1-DOPA on the sleep of man. Nature, 228: 999–1001, 1970.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuropsychopharmacology Research Unit Department of Psychiatry, New York University Medical Center, New York, USA

    Samuel Gershon, Burton Angrist & Baron Shopsin

Authors
  1. Samuel Gershon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Burton Angrist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Baron Shopsin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National Institute of Mental Health, Bethesda, Maryland, USA

    Elliot S. Gershon M.D.

  2. Jerusalem Mental Health Center Ezrath Nashim, Jerusalem, Israel

    Robert H. Belmaker M. D.  & Milton Rosenbaum M. D.  & 

  3. Harvard Medical School, Boston, Massachusetts, USA

    Seymour S. Kety M. D.

Rights and permissions

Reprints and permissions

Copyright information

© 1977 Plenum Press, New York

About this chapter

Cite this chapter

Gershon, S., Angrist, B., Shopsin, B. (1977). Pharmacological Agents as Tools in Psychiatric Research. In: Gershon, E.S., Belmaker, R.H., Kety, S.S., Rosenbaum, M. (eds) The Impact of Biology on Modern Psychiatry. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-0778-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-0778-5_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-0780-8

  • Online ISBN: 978-1-4684-0778-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation